Recent Press Releases

Amarin Provides Update on ANCHOR Trial SPA Agreement Rescission Appeal

Amarin Provides Update on ANCHOR Trial SPA Agreement Rescission Appeal BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 09/12/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical...

Cyclacel Pharmaceuticals, Inc. (CYCC) Appoints Samuel L. Barker, Ph.D. To Board Of Directors

Cyclacel Pharmaceuticals, Inc. (CYCC) Appoints Samuel L. Barker, Ph.D. To Board Of Directors BERKELEY HEIGHTS, N.J., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC)...

Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company

Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company Separation into two publicly traded companies remains on track for mid-2015 September 10, 2014 04:30 PM Eastern Daylight...

U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic Castration-Resistant Prostate Cancer

Approval Based on Improved Overall Survival, Delayed Time to Radiographic Progression and an Overall Positive Benefit-Risk Profile SAN FRANCISCO, CA and TOKYO, JAPAN -- (Marketwired) -- 09/10/14...

Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management

Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management New Medication for Obese Adults, or Overweight...

At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme's Lemtrada in Pivotal Studies

At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme's Lemtrada in Pivotal Studies In approximately 70 percent of patients, disability scores improved...

Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting

Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

First biosimilar insulin to receive regulatory approval in the EU

INDIANAPOLIS and RIDGEFIELD, Conn.,

Generic Pharmaceutical Savings Reach Highest-Ever Watermark of $239 Billion in 2013

Ten-year savings hits record at nearly $1.5 trillion according to annual Generic Drug Savings in the U.S. report WASHINGTON, DC (Sept. 10, 2014) — The Generic Pharmaceutical Association (GPhA)...

SPECIAL DRUG SAFETY REPORT DETAILS 49,000 PREVIOUSLY UNDISCLOSED SIDE EFFECT REPORTS

SPECIAL DRUG SAFETY REPORT DETAILS 49,000 PREVIOUSLY UNDISCLOSED SIDE EFFECT REPORTS REPORT AT TEDMED 2014 HIGHLIGHTS DATA MINING'S ROLE IN IMPROVING PUBLIC SAFETY SANTA ROSA, Calif., September 10,...

Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression

Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression New data showed patients who had the highest rates of brain...

FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension

FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension DUBLIN, Sept. 9, 2014 /PRNewswire/ -- Actavis plc...

Drug Launch, Market Activity, Appointments, and Special Meeting of Shareholders - Research Reports on Teva, Universal Health, Tenet, Allergan and Valeant

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 9, 2014<

The cost of nab-paclitaxel is not justified by its limited benefit, says NICE in draft guidance

The cost of nab-paclitaxel is not justified by its limited benefit, says NICE in draft guidance NICE has published new draft guidance which recommends that nab-paclitaxel taken with gemcitabine...

Pfizer Canada contributes EpiPen® (epinephrine) Auto-Injectors to Hamilton pilot project

Pfizer Canada contributes EpiPen® (epinephrine) Auto-Injectors to Hamilton pilot project City's pilot project to improve public health safety is first of its kind in Canada TORONTO, Sept. 8,...

Par Pharmaceutical Resumes Shipment of Generic Precedex® Injection

Par Pharmaceutical Resumes Shipment of Generic Precedex® Injection WOODCLIFF LAKE, N.J., Sept. 8, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has resumed...

FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease

FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease Approval aligns with Centers for Disease Control and Prevention's recommendations for...

Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibody Program from AnaptysBio

SHM-XEL Platform Successfully Generates Novel Therapeutic Approach to Autoimmune Disease

SAN DIEGO, Sept.

New Abbott Technology May Uncover the Root of Critical Infections and Cut Health Care Costs

-Innovative Abbott testing technology may help to identify severe infections sooner

WASHINGTON, Sept.